Key facts
- Notable investors include Gaingels, Case Western Reserve University, Emory University, Georgia Research Alliance, Ventac Partners.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for RORA Biologics
- ·The full record, as it builds
Funding rounds
No funding rounds for RORA Biologics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RORA Biologics
Developer of a T-cell platform designed to provide innovative cell therapies, including genetically engineered chimeric antigen receptor T cells, to treat cancer patients. The company's platform offers recently discovered stem cell-like memory T cells to make chimeric antigen receptor drugs more durable, safer, and long-lasting, along with a stand-alone therapy to reconstitute the immune system affected by human immunodeficiency virus infection, enabling healthcare professionals to improve treatment for patients.
- Sector
- Healthcare
- HQ
- Atlanta, GA, United States
- Founded
- 2021
- Employees
- 4
- Website
- rorabio.com/
- Ownership
- Privately Held (backing)
RORA Biologics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RORA Biologics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RORA Biologics in its N-PORT filings yet. We sweep new filings monthly.